The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Given the probability of trial success and current valuation, we rate the ATYR stock 'Hold' as risk and reward appear ...

Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

SLC35B1 transports ATP into the ER, and its structure offers potential for targeted therapies in diseases linked to ER stress ...

The appendix may play a further role in protecting the gastrointestinal system from invading pathogens. This would explain ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

National Institutes of Health Director Jay Bhattacharya claimed the dean of Stanford Medical School asked him to stop ...

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical ...

A compound derived from rosemary, known as carnosic acid, has been transformed into a potent brain-boosting drug that combats Alzheimer’s by reducing inflammation and stress in the brain — all while ...

Mediar Therapeutics doses first patient in phase 2 WISPer trial of MTX-463 for idiopathic pulmonary fibrosis: Boston Monday, June 9, 2025, 15:00 Hrs [IST] Mediar Therapeutics, Inc ...